AKT1 and diabetes mellitus: • lapatinib inhibits EGFR & ErbB2 activity in diabetic MVB and in VSMCs and reverses diabetes and hyperglycemia-induced changes in ERKs, ROCK, AKT, FOXO, eNOS, & NF-kB and prevents HG-induced apoptosis in VSMCs